Skip to Content

Generic Zurampic Availability

Zurampic is a brand name of lesinurad, approved by the FDA in the following formulation(s):

ZURAMPIC (lesinurad - tablet;oral)

  • Manufacturer: IRONWOOD PHARMS INC
    Approval date: December 22, 2015
    Strength(s): 200MG [RLD]

Has a generic version of Zurampic been approved?

No. There is currently no therapeutically equivalent version of Zurampic available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zurampic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
    Patent 8,003,681
    Issued: August 23, 2011
    Inventor(s): Girardet; Jean-Luc & Koh; Yung-Hyo
    Assignee(s): Ardea Biosciences, Inc.
    A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Patent expiration dates:
    • August 25, 2025
      ✓ 
      Drug substance
  • Compounds and compositions and methods of use
    Patent 8,084,483
    Issued: December 27, 2011
    Inventor(s): Quart; Barry D. & Girardet; Jean-Luc & Gunic; Esmir & Yeh; Li-Tain
    Assignee(s): Ardea Biosciences, Inc.
    Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Patent expiration dates:
    • August 17, 2029
      ✓ 
      Patent use: REDUCTION OF SERUM URIC ACID LEVELS
  • Compounds and compositions and methods of use
    Patent 8,283,369
    Issued: October 9, 2012
    Inventor(s): Quart; Barry D. & Girardet; Jean-Luc & Gunic; Esmir & Yeh; Li-Tain
    Assignee(s): Ardea Biosciences. Inc.
    Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Patent expiration dates:
    • November 26, 2028
      ✓ 
      Patent use: TREATMENT OF GOUT
    • November 26, 2028
      ✓ 
      Patent use: ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
  • Compounds and compositions and methods of use
    Patent 8,357,713
    Issued: January 22, 2013
    Assignee(s): Ardea Biosciences Inc.
    Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Patent expiration dates:
    • November 26, 2028
      ✓ 
      Patent use: REDUCTION OF SERUM URIC ACID LEVELS
      ✓ 
      Drug product
    • November 26, 2028
      ✓ 
      Patent use: TREATMENT OF HYPERURICEMIA
      ✓ 
      Drug product
    • November 26, 2028
      ✓ 
      Patent use: TREATMENT OF GOUT
      ✓ 
      Drug product
  • Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
    Patent 8,546,436
    Issued: October 1, 2013
    Assignee(s): Ardea Biosciences, Inc.
    Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Patent expiration dates:
    • February 29, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds and compositions and methods of use
    Patent 8,546,437
    Issued: October 1, 2013
    Assignee(s): Ardea Biosciences, Inc.
    Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Patent expiration dates:
    • April 29, 2029
      ✓ 
      Patent use: TREATMENT OF HYPERURICEMIA
  • Treatment of gout and hyperuricemia
    Patent 9,216,179
    Issued: December 22, 2015
    Assignee(s): ARDEA BIOSCIENCES, INC.
    Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
    Patent expiration dates:
    • August 1, 2031
      ✓ 
      Patent use: COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 22, 2020 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide